patents
You are viewing stuff tagged with patents.
You are viewing stuff tagged with patents.
The patent for Abacavir (ABC) (trade name Ziagen), a reverse transcriptase inhibitor (RTI) effective against some resistant strains of HIV, expires this December. Incidentally, a guest lecturer in microbiology came to us to speak about HIV. Here’s where it gets interesting:
Using public funds, researchers at the University of Minnesota analyzed primary literature and hypothesized a novel RTI. After testing revealed its efficacy, Abacavir was patented. GlaxoSmithKline then sold the drug as Ziagen… without proper rights to do so. Mark Yudof, president of the University in the late 90s (and a lawyer), decided to sue for royalties. Settlement: 400 million dollars. This is the largest intellectual property case in the U of M’s history.